$木薯科学(SAVA)$ On March 31, 2024,{Cassava Sciences} will announce top-line results for their recent Phase 3 trial for Simufilam - (CMS).

2023年5月11日，Cassava Sciences, Inc.宣布Simufilam在超过125名阿尔茨海默病患者中进行的为期6个月的随机对照试验完成患者给药。这项试验被称为“认知维持研究”（CMS）。针对阿尔茨海默病痴呆症的研究性口服药物治疗。CMS旨在评估simufilam对轻度至中度阿尔茨海默病痴呆患者的安全性和疗效，其采用了随机抽样研究设计。Cassava Sciences预计将在2023年第三季度宣布CMS的顶线数据。现调整为2024-3-31.

Simufilam是一款口服小分子化合物，它的靶点不是β淀粉样蛋白，而是通过与细丝蛋白A（FLNA）结合，恢复它的正常构象和功能，阻止β淀粉样蛋白片段（Aβ42）的信号传导，具有同时减少神经变性和神经炎症的潜力。

结构参考：网页链接

The community is currently bullish on the prospects of progression, as all three community members weighing in on this drug believe it will move forward.

The announcement certainly didn’t help the company's stock price today. Cassava Sciences careened $1.03 (-5.31%) to $18.38 on heavy volume today. It actually opened the day up before starting its big sell-off.

当天市场下跌了5.31%。